NeuroIntact
NeuroIntact is a medical device company based in Baltimore, Maryland, focused on developing targeted temperature management (TTM) therapies to preserve neurological function in critical care settings, including stroke, traumatic brain injury, and cardiac arrest. The company specializes in intranasal delivery of TTM, aiming to optimize brain temperature while minimizing systemic effects and side effects seen with whole-body cooling. Backed by recent funding and industry partnerships, NeuroIntact is advancing its devices through clinical evaluation and commercialization, with a focus on improving patient outcomes and care for both military and civilian populations.
NeuroIntact
1100 Wicomico Street, Suite 330, Baltimore, MD 21230
Patents
What We Do
A non-invasive medical device enabling regional cooling of the brain via intranasal delivery, intended for use in neurocritical care settings such as stroke, traumatic brain injury, and cardiac arrest.
A non-invasive medical device enabling regional cooling of the brain via intranasal delivery, intended for use in neurocritical care settings such as stroke, traumatic brain injury, and cardiac arrest.
Application Area
Digital Health Technologies
Key People
News & Updates
Received $250,000 seed funding from TEDCO to advance development of solutions for managing cerebral edema and intracranial pressure with targeted temperature management.
Collaboration on a $999,962 US Marine Corps contract for technology development in intranasal cooling for traumatic brain injury prevention in combat casualties.
Met safety and efficacy endpoints in animal studies for targeted temperature management device.
Article analyzing outcomes of patients treated with targeted temperature management following out-of-hospital cardiac arrest using clinical data from 24 hospitals.
Overview of a consensus developed by neuro intensive care experts on the use of targeted temperature management in intracerebral haemorrhage, subarachnoid haemorrhage, and acute ischemic stroke.
A company-hosted event featuring a presentation on the latest advances, investment considerations, and progress of NeuroIntact's targeted temperature management technology. Attendees included key opinion leaders and potential investors.
Received $250,000 seed funding from TEDCO to advance development of solutions for managing cerebral edema and intracranial pressure with targeted temperature management.
Collaboration on a $999,962 US Marine Corps contract for technology development in intranasal cooling for traumatic brain injury prevention in combat casualties.
Met safety and efficacy endpoints in animal studies for targeted temperature management device.
Article analyzing outcomes of patients treated with targeted temperature management following out-of-hospital cardiac arrest using clinical data from 24 hospitals.
Overview of a consensus developed by neuro intensive care experts on the use of targeted temperature management in intracerebral haemorrhage, subarachnoid haemorrhage, and acute ischemic stroke.
A company-hosted event featuring a presentation on the latest advances, investment considerations, and progress of NeuroIntact's targeted temperature management technology. Attendees included key opinion leaders and potential investors.